

# CONTROVERSIES IN DIALYSIS ACCESS

December 11-12, 2021  
Dallas, TX

This activity is jointly provided by Clinical and Patient Educators Association and Ortnok.

This activity is provided by an educational grant from: Medtronic, W.L. Gore, Becton, Dickinson, and Company, Inari Medical, and Cook Medical



## **Target Audience**

This activity is intended for healthcare workers involved with Dialysis Access such as: Transplant Surgeons, Vascular Surgeons, Nephrologists, Interventionalists (Radiologists, nephrologists), Primary Care Physicians, Dialysis nurses and technologists.

## **Statement of Need/Program Overview**

Controversies in Dialysis Access (CiDA) is an international symposium that was started, and is still co-directed, by Drs. Davidson and Dolmatch. We believe that impactful education can also be entertaining and enjoyable. This is what sets CiDA apart. CiDA is the leading educational forum for surgeons, radiologists, nephrologists, and medical staff who care for dialysis access patients. We are not a "society," nor a University. We welcome everyone. We embrace controversy, reject bias, and invite input from faculty and attendees alike. The mission is to address challenging issues surrounding end-stage renal disease, renal replacement, and dialysis access.

## **Educational Objectives**

*After completing this activity, learners should be better able to:*

- Discuss the power of teamwork affecting patient quality of life, and outcomes
- Identify an objective algorithm focused on outcomes
- Review the impact of research study design on results and conclusions
- List new procedures, devices and policies approved or in progress from FDA, CMS, and other governing institutions

## **Faculty**

<b>Faculty</b>	<b>Affiliation</b>
Michael Allon	University of Alabama at Birmingham
Saravanan Bala	PPG Health - Associate Professor of Nephrology
Gerry Beathard	University of Texas medical Branch
David Cull	Prisma Health
Ingemar Davidson	Kidney Academy
Bart Dolmatch	The Palo Alto Medical Foundation
Paul Gibbs	Wessex Kidney Centre, QA Hospital, Portsmouth, UK
James Gilbert	Oxford University Hospitals NHS Trust
Ziv Haskal	University of Virginia School of Medicine
Ulf Hedin	Karolinska Institute

Steve Hohmann	Baylor Scott & White, Dallas, Texas
Jeff Hull	Richmond Vascular Center
William Jennings	University of Oklahoma, School of Community Medicine, Tulsa
Ari Kramer	Spartanburg Hospital System
Robert E Lee	US Food and Drug Administration
Robert Lookstein	Icahn School of Medicine at Mount Sinai
Neghae Mawla	Dallas Nephrology Associates
Richard Neville	Inova Health System
Mohamed amine Rahil	Bachir ben nacer Hospital, Biskra, Algeria
Robert Shahverdyan	Vascular Access Center, Asklepios Clinic Barmbek, Hamburg, Germany
Michael Tal	Hadassah Hospital Jerusalem Israel
Scott Trerotola	Penn Medicine

### Program Agenda

12/11/2021	9:00 - 9:50	<b>Percutaneous AVFs – Ready for prime time?</b>
12/11/2021		Intro
12/11/2021		WaveLinQ and Ellipsys
12/11/2021		Surgical perspective
12/11/2021		Percutaneous AV Fistula Devices: a regulatory perspective
12/11/2021	10:00 - 10:50	<b>AV Fistulae – No better than AV Grafts?</b>
12/11/2021		Intro
12/11/2021		Swedish AVF
12/11/2021		Midhigh Grafts
12/11/2021		AVFs are overrated
12/11/2021		Development and Preliminary Validation of an Evidence-based, Bedside Tool to Guide Vascular Access Placement
12/11/2021		Q&A
12/11/2021	14:00 - 14:50	<b>Home Dialysis – It will never be mainstream!</b>
12/11/2021		Intro
12/11/2021		Remote Monitoring - Key to Home Dialysis
12/11/2021		Q&A
12/11/2021	15:00 - 15:50	<b>DCBs – Worthwhile for anyone?</b>
12/11/2021		Intro
12/11/2021		Lutonix AV: The Global Trial
12/11/2021		In.Pact AV: The Global Trial
12/11/2021		The “Swinnen” Trial
12/11/2021		Q&A
12/11/2021	16:00 - 16:50	<b>PTA, DCB, or Covered Stent - Competing or Complementary?</b>
12/11/2021		Intro
12/11/2021		Is PTA better than we thought?
12/11/2021		What We've Learned about Covered stents in AV Access
12/11/2021		What We've Learned about DCB's in AV Access
12/11/2021		Cephalic vein arch - Data for best treatment
12/11/2021		Juxta anastomotic stenosis – Data driven treatment (or Noise, Nonsense, and Nuance)

12/11/2021		Use of Covered stents and DCB's in the OBL and ASC Setting: What Makes Sense?
12/11/2021		Q&A
12/12/2021		<b>Cases Managed by the Experts: Where data meets the patient</b>
12/12/2021		Case 12 – Hand Ischemia
12/12/2021		How Much is Too Much
		Paradoxical migration of an arterial embolus upstream from the fistula during a percutaneous thrombectomy procedure.
12/12/2021	10:00 -11:45	Poor flows in a RC fistula
12/12/2021		<b>Continuation of Case Discussions</b>
12/12/2021		Endo-AVF Success??
12/12/2021		74 yo woman with ESRD HTN, Type II DM with nephropathy
12/12/2021	13:30 - 15:30	Cases - Dolmatch

### **Physician Accreditation Statement**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and Ortnok. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

### **Physician Credit Designation**

CPEA designates this live activity for a maximum of 8.25 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **CPEA Contact Information**

For information about the accreditation of this program, please contact CPEA at 303-953-4580 or [inquire@cpea-assn.org](mailto:inquire@cpea-assn.org).

### **Instructions for Obtaining Credit**

To receive credit, participants must complete and submit the evaluation: <https://www.surveymonkey.com/r/CiDA2021>. Upon completion, participants will be able emailed their certificate within 2-4 weeks.

### **Disclosure of Conflicts of Interest**

Clinical and Patient Educators Association (CPEA) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by CPEA are required to disclose all financial relationships with any ineligible company within the past 24 months to CPEA. All financial relationships reported are identified as relevant and mitigated by CPEA in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by CPEA to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The **faculty** have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Relevant Financial Relationship
Michael Allon	<b>Consulting Fee: (e.g., Advisory Board):</b> CorMedix
Saravanan Bala	Nothing to disclose
Gerry Beathard	Nothing to disclose
David Cull	<b>Honoraria:</b> Gore <b>Other:</b> Gore Medical provided an educational grant supporting the development of a medical app I will be discussing at the conference. The mobile app is free and has no commercial value to Gore Medical or to me. Gore Medical is not advertised on the mobile app.
Ingemar Davidson	Nothing to disclose
Bart Dolmatch	<b>Consulting Fee (e.g., Advisory Board):</b> Becton Dickinson Inc, Medtronic Inc, Merit Medical Systems Inc, Alio Inc, Inari Inc, Black Swan Vascular Inc, Venova Inc <b>Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed):</b> Alio Inc, Black Swan Vascular Inc, Merit Medical Systems Inc, Venova Inc <b>Royalty:</b> Merit Medical Systems Inc
Paul Gibbs	<b>Consulting Fee (e.g., Advisory Board):</b> BD Bard, Medtronic <b>Honoraria:</b> Syner-Med
James Gilbert	<b>Consulting Fee (e.g., Advisory Board):</b> Merit Medical, BD BARD <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Merit Medical <b>Honoraria:</b> Merit Medical, BD BARD <b>Speakers' Bureau:</b> Boehringer Ingelheim
Ziv Haskal	<b>Consulting Fee (e.g., Advisory Board):</b> Becton Dickinson, WL Gore and Associates, Sirtex, Boston Scientific, Bendit <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Siemens, Ethicon
Ulf Hedin	Nothing to disclose

Steve Hohmann	<p><b>Consulting Fee (e.g., Advisory Board):</b> BD, Gore, Medtronic, Merit</p> <p><b>Honoraria:</b> BD, Gore, Medtronic, Merit</p> <p><b>Speakers' Bureau:</b> BD, Gore, Medtronic, Merit</p>
Jeff Hull	<p><b>Consulting Fee (e.g., Advisory Board):</b> Medtronic</p> <p><b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Medtronic</p>
William Jennings	<p><b>Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed):</b> Past stock ownership in Avenu Medical (now part of Medtronic)</p>
Ari Kramer	<p><b>Consulting Fee (e.g., Advisory Board):</b> Medtronic, Sonavex</p> <p><b>Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed):</b> Medtronic</p>
Robert E Lee	Nothing to disclose
Robert Lookstein	<p><b>Consulting Fee (e.g., Advisory Board):</b> Medtronic, Boston Scientific, Penumbra, Neptune, Truic, Becton Dickinson</p> <p><b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Medtronic</p> <p><b>Speakers' Bureau:</b> Medtronic, Boston Scientific</p>
Neghae Mawla	<p><b>Consulting Fee (e.g., Advisory Board):</b> BD, Medtronic</p> <p><b>Speakers' Bureau:</b> BD, Medtronic</p>
Richard Neville	Nothing to disclose
Mohamed amine Rahil	Nothing to disclose
Robert Shahverdyan	<p><b>Honoraria:</b> Avenu medical, BD/C.R.Bard, Medtronic, Laminate Medical</p> <p><b>Speakers' Bureau:</b> Avenu medical, BD/C.R.Bard, Medtronic, Laminate Medical</p>
Michael Tal	Nothing to disclose
Scott Trerotola	<p><b>Consulting Fee (e.g., Advisory Board):</b> MedComp, BD Bard, Cook</p> <p><b>Royalty:</b> Teleflex</p>

The *planners and managers* have the following relevant financial relationships with ineligible companies:

<b><i>Name of Planner or Manager</i></b>	<b><i>Reported Financial Relationship</i></b>
Ingemar Davidson	Nothing to disclose
Bart Dolmatch	<b>Consulting Fee (e.g., Advisory Board):</b> Becton Dickinson Inc, Medtronic Inc, Merit Medical Systems Inc, Alio Inc, Inari Inc, Black Swan Vascular Inc, Venova Inc <b>Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed):</b> Alio Inc, Black Swan Vascular Inc, Merit Medical Systems Inc, Venova Inc <b>Royalty:</b> Merit Medical Systems Inc
Andrea Funk	Nothing to disclose

**Disclosure of Unlabeled Use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Clinical and Patient Educators Association (CPEA) and Institute for Patient Access do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

**Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.